Background Cancer-associated isocitrate dehydrogenase (IDH) mutations block normal
cellular differentiation via production of the oncometabolite, R-2-hydroxyglutarate. In patients …

Epigenetics refers to the regulation of gene expression mainly by changes in DNA
methylation and modifications of histone proteins without altering the actual DNA sequence …

Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that
produce the oncometabolite D-2-hydroxyglutarate (2-HG) occur frequently in human acute …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …

Assessment of minimal residual disease has emerged as a powerful prognostic factor in
acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as …

Contribution: FS designed and performed experiments, analyzed data and reviewed the
paper; JS, LA and MBD analyzed materials and data, and reviewed the manuscript; CL and …

The development and approval of novel substances have resulted in substantial
improvements in the treatment of acute myeloid leukemia (AML). In the current era of novel …

Acute myeloid leukemia (AML) is a lethal hematologic malignancy associated with poor
clinical outcomes. In recent years, mutations in the IDH1 and IDH2 genes have been …

A characteristic feature of leukemia cells is a blockade of differentiation at a distinct stage in
cellular maturation. In the 1970s and 1980s, studies demonstrating the capabilities of certain …

Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and
proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities …